Additionally, the prevalence of SARS-CoV-2 IgG/IgM antibodies in MS is low, and, thus, this population is especially vulnerable to future COVID-19 infections in the case of additional epidemic waves and/or local outbreaks. This evidence concerns the gene CD40LG and myeloid sarcoma.